Clinical data | |
---|---|
Other names | KX-826 |
Routes of administration | Topical |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C21H15F5N4O2S |
Molar mass | 482.43 g·mol−1 |
3D model (JSmol) | |
| |
|
Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of androgenic alopecia (androgen-dependent scalp hair loss)[1][2][3] As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.[2]
The primary endpoint is the change from baseline in non-vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 10 mg (0.5% BID) per patient per day in the trial.[4]
Pyrilutamide is generally well-tolerated. The most common adverse event is contact dermatitis.[5]
Pyrilutamide binds to the androgen receptor with a very high affinity with an IC50 of 0.28 nM. [3] Reference drug bicalutamide had an IC50 of 3.1 nM. [3]